NCT03463252View on ClinicalTrials.gov

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2030

Conditions
Endometrial CancerAtypical Endometrial Hyperplasia
Interventions
DRUG

Progesterone

MPA oral 250mg-500mg qd for 3 months per cycle

DEVICE

Mirena®

levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle

DRUG

GnRH agonist

GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle

Trial Locations (1)

610000

RECRUITING

West China Second University Hospital, Chengdu

All Listed Sponsors
lead

West China Second University Hospital

OTHER